Ranbaxy gets nod from USFDA to market its two products

New Delhi, Jan 31 (UNI) Ranbaxy Pharmaceuticals Inc (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd (RLL), today received approval from the US Food and Drug Administration (USFDA) to market Amoxicillin and Clavulanate Potassium for oral suspension USP.

The division of bioequivalence has determined the Ranbaxy formulation to be bioequivalent and therefore, therapeutically equivalent to Augmentin(r) ES-600 for oral suspension.

Augmentin(r) ES-600 for oral suspension has combined sales of 216 million dollars in the suspension market.

''This move demonstrates our depth and breadth of expertise to add to our ever expanding product portfolio, along with our commitment to bring affordable generic alternatives to the US healthcare system,'' said Vice President of Sales and Marketing for RPI Jim Meehan.

He further added that yet another product that has clinical utility and value will be added and as such, will distinguish Ranbaxy in the years to come. These product will be available in the market from April 2007.

Ranbaxy Pharmaceuticals Inc (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Ltd (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

UNI